Skip to main content
SpringerLink
Log in

Therapeutic Aspects of Polycystic Ovary Syndrome in Adolescence

  • Chapter
Insulin Resistance and Polycystic Ovarian Syndrome

Part of the book series: Contemporary Endocrinology ((COE))

  • 1335 Accesses

Abstract

Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, chronic anovulation, and insulin resistance. The syndrome manifests with hirsutism, irregular menses, infertility, dyslipidemia, as well as a higher risk for type 2 diabetes mellitus, and cardiovascular disease. PCOS has a pubertal onset. The clinical signs and neuroendocrine features of adolescents with PCOS resemble those found in adult women with the syndrome. Early recognition and prompt treatment in adolescents is essential for preventing long-term consequences. This chapter reviews the clinical, hormonal, and metabolic features of PCOS in adolescence and current treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the greek island of Lesbos: hormonal and metabolic pofile. J Clin Endocrinol Metab 1999;84:4006–4011.

    Article  CAS  PubMed  Google Scholar 

  2. Ehrmann DA. Obesity and glucose intolerance in androgen excess. In: Azziz R, Nestler JE, Dewailley D, eds. Androgen Excess Disorders in Women. Philadelphia, PA: Lipincott-Raven, 1997, pp. 705–712.

    Google Scholar 

  3. Legro RS. Polycystic ovary syndrome. Phenotype to genotype. Endocrinol Metab Clin North Am 1999;28:379–396.

    Article  CAS  PubMed  Google Scholar 

  4. Franks S, Gharani N, McCarthy M. Genetic abnormalities in polycystic ovary syndrome. Ann Endocrinol (Paris) 1999;60:131–133.

    CAS  Google Scholar 

  5. Apter D, Butzow T, Laughlin GA, Yen SS. Accelerated 24-hour LH pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome. J Clin Endocrinol Metab 1994;79:119–125.

    Article  CAS  PubMed  Google Scholar 

  6. Homburg R, Lambalk CB. Polycystic ovary syndrome in adolescence: a therapeutic conundrum. Hum Reprod 2004;19:1–4.

    Article  Google Scholar 

  7. van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteninizing hormone, androgens, and insulin. Fertil Steril 2000;74:49–58.

    Article  PubMed  Google Scholar 

  8. van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Endocrine features of polycystic ovary syndrome in a random population sample of 14–16 year old adolescents. Hum Reprod 1999;14:2223–2239.

    Article  PubMed  Google Scholar 

  9. Avvad CK, Holeuwerger R, Silva VCG, Bordallo MAN, Breitenbach MMD. Menstrual irregularity in the first postmenarchal years: an early clinical sign of polycystic ovary syndrome in adolescence. Gynecol Endocrinol 2001;15:170–177.

    CAS  PubMed  Google Scholar 

  10. Herter LD, Magalhaes JA, Spritzer PM. Relevance of the determination of ovarian volume in adolescent girls with menstrual disorders J Clin Ultrasound 1996;24:243–248.

    Article  CAS  PubMed  Google Scholar 

  11. Venturoli S, Porcu E, Fabbri R, et al. Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Pediatr Res 1995;38:974–980.

    Article  CAS  PubMed  Google Scholar 

  12. Apter D, Butzow T, Laughlin GA, Yen SS. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab 1995;80:2966–2973.

    Article  CAS  PubMed  Google Scholar 

  13. Miller WL. The molecular basis of premature adrenarche: an hypothesis. Acta Paediatr Suppl 1999; 88:60–66.

    Article  CAS  PubMed  Google Scholar 

  14. Zhang LH, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci USA 1995;92:10,619–10,623.

    Article  CAS  PubMed  Google Scholar 

  15. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995;96:801–810.

    Article  CAS  PubMed  Google Scholar 

  16. Kent SC, Legro RS. Polycystic ovary syndrome in adolescents. Adolesc Med 2002;13:73–88.

    PubMed  Google Scholar 

  17. Ibanez L, Vall C, Potau N, Marcus MV, de Zegher F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 2000;85:3526–3530.

    Article  CAS  PubMed  Google Scholar 

  18. Brigdes NA, Cooke A, Healy MR, Hindmarsh PC, Brook CGD. Standards of ovarian volume in childhood and puberty. Fertil Steril 1993;60:456–460.

    Google Scholar 

  19. Dramusic V, Rajan U, Chan P, Ratnam SS, Wong YC. Adolescent polycystic ovary syndrome. Ann N Y Acad Sci 1997;816:194–208.

    Article  CAS  PubMed  Google Scholar 

  20. Silfen ME, Denburg MR, Manibo AM, et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 2003;88:4682–4688.

    Article  CAS  PubMed  Google Scholar 

  21. Koivunen RM, Morin-Papunen LC, Ruokonen A, Tapanainen JS, Martikainen HK. Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome. Hum Reprod 2001;16:2546–2551.

    Article  CAS  PubMed  Google Scholar 

  22. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to isulin reduction with decreases in ovarian P450c 17α activity and serum androgens. J Clin Endocrinol Metab 1997; 82:4075–4079.

    Article  CAS  PubMed  Google Scholar 

  23. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaird glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002;87:1555–1559.

    Article  CAS  PubMed  Google Scholar 

  24. Adams J, Polson DW, Abdulwahid N. Multifollicular ovaries: clinical and endocrine features and response to gonadotropin releasing hormone. Lancet 1985;2:1375–1378.

    Article  CAS  PubMed  Google Scholar 

  25. Polson DW, Wadsworth J, Adams J. Polycystic ovaries — a common finding in normal women. Lancet 1988;1:870–872.

    Article  CAS  PubMed  Google Scholar 

  26. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;87:1017–1023.

    Article  Google Scholar 

  27. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and β-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab 2001;86:66–71.

    Article  CAS  PubMed  Google Scholar 

  28. Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr 2001;138:38–44.

    Article  CAS  PubMed  Google Scholar 

  29. Pasquali R, Gambineri A, Antocetani B, et al. The natural history of metabolic syndrome 18 and the effect of long-term oestrogen-progestogen treatment. Clin Endocrinol (Oxf) 1999;50:517–527.

    Article  CAS  Google Scholar 

  30. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;37:119–125.

    Article  CAS  Google Scholar 

  31. Robinson S, Henderson AD, Gelding SV, et al. Dyslipidemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf) 1996;44:277–284.

    Article  CAS  Google Scholar 

  32. Mastorakos G, Koliopoulos K, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives Fertil Steril 2002;77:919–927.

    Article  PubMed  Google Scholar 

  33. Norman RJ, Masters SC, Hague W, Beng C, Pannall P, Wang IX. Metabolic approaches to the subclassification of the polycystic ovary syndrome. Fertil Steril 1995;63:329–335.

    CAS  PubMed  Google Scholar 

  34. Wild RA. Obesity, lipids, cardiovascular risk and androgen excess. Am J Med 1995;98:27S–32S.

    Article  CAS  PubMed  Google Scholar 

  35. Balfour JA, McClellan K. Topical eflornithine. Am J Clin Dermatol 2001;2:197–201.

    Article  CAS  PubMed  Google Scholar 

  36. Vexiau P, Chaspoux C, Boudou P, et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol 2002;146:992.

    Article  CAS  PubMed  Google Scholar 

  37. Murphy AA, Cropp CS, Smith BS, Burkman RT, Zacar HA. Effect of low dose oral contraceptive on gonadotropins, androgens and sex hormone binding globulin in non-hirsute women. Fertil Steril 1990;53:35–39.

    CAS  PubMed  Google Scholar 

  38. Dewis P, Petsos P, Newman M, Anderson DC. The treatment of hirsutism with a combination of desogestrel and ethinyl oestradiol. Clin Endocrinol 1985;22:29–36.

    Article  CAS  Google Scholar 

  39. Miller JA, Jacobs HS. Treatment of hirsutism and acne with cyproterone acetate. Cin Endocrinol Metab 1986;15:373–389.

    Article  CAS  Google Scholar 

  40. Falsetti L, Dordoni D, Gastaldi C, Gastaldi A. A new association of ethinylestradiol (0.035mg) cyproterone acetate (2mg) in the therapy of polycystic ovary syndrome Acta Eur Fertil 1986;17:19–25.

    CAS  PubMed  Google Scholar 

  41. Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum Reprod 2001;16:36–42.

    Article  CAS  PubMed  Google Scholar 

  42. Prelevic GM, Wurzburger MI, Balint-Peric L, Puzigaca Z. Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on clinical signs of androgenization, hormone profile and ovarian size in patients with polycystic ovary syndrome. Gynecol Endocrinol 1989;3:269–280.

    Article  CAS  PubMed  Google Scholar 

  43. Creatsas G, Koliopoulos C, Mastorakos G. Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. Ann NY Acad Sci 2000;900:245–252.

    CAS  PubMed  Google Scholar 

  44. Guido M, Romualdi D, Giuliani M, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004;89:2817–2823.

    Article  CAS  PubMed  Google Scholar 

  45. Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004;74:123–130.

    PubMed  Google Scholar 

  46. Thorneycroft IH. Evolution of progestins. Focus on the novel progestin drospirenone. J Reprod Med 2002;47:975–980.

    CAS  PubMed  Google Scholar 

  47. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002;69:2–15.

    PubMed  Google Scholar 

  48. Palep-Singh M, Mook K, Barth J, Balen A. An observational study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care 2004;30:163–165.

    Article  PubMed  Google Scholar 

  49. Cibula D, Hill M, Fanta M, Sindelka G, Zinvy J. Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome? Hum Reprod 2001;16:940–944.

    Article  CAS  PubMed  Google Scholar 

  50. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2003;88:148–156.

    Article  CAS  PubMed  Google Scholar 

  51. Falsetti L, Pasinetti E. Effects of long: term administration of an oral contraceptive containing ethinylestrdiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 1995;74:56–60.

    Article  CAS  PubMed  Google Scholar 

  52. Prelevic GM, Wurzburger MI, Trpkovic D, Balint-Peric L. Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome. Gynecol Endocrinol 1990;4:157–168.

    Article  CAS  PubMed  Google Scholar 

  53. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990;323:1375–1381.

    Article  CAS  PubMed  Google Scholar 

  54. Korytkowski MT, Mokan M, Horwitz MJ, Berga SL. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995;80:3327–3334.

    Article  CAS  PubMed  Google Scholar 

  55. Gaspard U, Scheen A, Endrikat J, et al. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception 2003;67:423–429.

    Article  CAS  PubMed  Google Scholar 

  56. Ludicke F, Gaspard UJ, Demeyer F, Scheen A, Lefebvre P. Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism. Contraception 2002;66:411–415.

    Article  CAS  PubMed  Google Scholar 

  57. Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin N Am 2005;34:677–705.

    Article  Google Scholar 

  58. Dawber RPR, Sinclair RD. Hirsuties. Clin Dermatol 2001;19:189–199.

    Article  CAS  PubMed  Google Scholar 

  59. Barth JH, Cherry CA, Wojnarowska F, Dawber RP. Cyproterone acteate for severe hirsutism. J Clin Endocrinol Metab 1991;35:5–10.

    CAS  Google Scholar 

  60. Venturoli S, Paradisi R, Bagnoli A, et al. Low-dose flutamide (125mg/day) as maintenance therapy in the treatment of hirsutism. Horm Res 2001;56:25–31.

    Article  CAS  PubMed  Google Scholar 

  61. Spritzer PM, Lisboa KO, Mattielo S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf) 2000;52:587–594.

    Article  CAS  Google Scholar 

  62. Barth JH, Cherry CA, Wojnaroswka F, Dawber RP. Spironolactone is an effective and well tolerated systemic antiandrogen therapy for hirsute women. J Clin Endocrinol Metab 1989;68:966–970.

    Article  CAS  PubMed  Google Scholar 

  63. Wong IL, Morris RS, Chang L, Spahn MA, Stanczyk FZ, Lobo RA. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 1995;80:233–238.

    Article  CAS  PubMed  Google Scholar 

  64. Tartagni M, Schonauer LM, De Salvia MA, Cicinelli E, De Pergola G, D’Addario V. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril 2000;73:718–723.

    Article  CAS  PubMed  Google Scholar 

  65. De Leo V, Fulghesu AM, la Marca A, et al. Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism. Gynecol Endocrinol 2000;14:411–416.

    Article  PubMed  Google Scholar 

  66. Castelo-Branco C, Martinez de Osaba MJ, Pons F, Fortuny A. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormone profile after 1-year use. Metabolism 1997;46:437–440.

    Article  CAS  PubMed  Google Scholar 

  67. Kahn JA, Gordon CM. Polycystic ovary syndrome. Adolesc Med 1999;10:321–336.

    CAS  PubMed  Google Scholar 

  68. Armstrong VL, Wiggam MI, Ennis CN, et al. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol / cyproterone acetate. QJM 2001;94:31–37.

    Article  CAS  PubMed  Google Scholar 

  69. Diamanti-Kandarakis E, Zapanti E. Insulin sensitizers and antiandrogens in the treatment of polycystic ovary syndrome. Ann NY Acad Sci 2000;900:203–212.

    CAS  PubMed  Google Scholar 

  70. Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767–2774.

    Article  CAS  PubMed  Google Scholar 

  71. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebocontrolled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139–146.

    Article  CAS  PubMed  Google Scholar 

  72. Loverro G, Lorusso F, De Pergola G, Nicolardi V, Mei L, Selvaggi L. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. Gynecol Endocrinol 2002;16:217–224.

    CAS  PubMed  Google Scholar 

  73. Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:4116–4123.

    Article  CAS  PubMed  Google Scholar 

  74. Heard MJ, Pierce A, Carson SA, Buster JE. Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fertil Steril 2002;77:669–673.

    Article  PubMed  Google Scholar 

  75. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001;75:310–315.

    Article  CAS  PubMed  Google Scholar 

  76. Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002;77:520–525.

    Article  CAS  PubMed  Google Scholar 

  77. Glueck CJ, Philips H, Cameron D, Sieve Smith L, Wang P. Continuing metformin throughout pregmancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: apilot study. Fertil Steril 2001;75:46–52.

    Article  CAS  PubMed  Google Scholar 

  78. Glueck CCJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin to restore normal menses in oligoamenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 2001;29:160–169.

    Article  CAS  PubMed  Google Scholar 

  79. Azziz R, Ehrman D, Legro R, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86:1626–1632.

    Article  CAS  PubMed  Google Scholar 

  80. Cataldo NA, Abbasi F, McLaughlin TL, Lamendola C, Reaven GM. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertil Steril 2001;76:1057–1059.

    Article  CAS  PubMed  Google Scholar 

  81. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibriolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2108–2116.

    Article  CAS  PubMed  Google Scholar 

  82. Belli SH, Graffigna MN, Oneto A, Otero P, Schurman L, Levalle OA. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 2004;81:624–629.

    Article  CAS  PubMed  Google Scholar 

  83. Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 2005;90:60–65.

    Article  CAS  PubMed  Google Scholar 

  84. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004;82:893–902.

    Article  CAS  PubMed  Google Scholar 

  85. Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:3835–3840.

    Article  CAS  PubMed  Google Scholar 

  86. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003;27:1437–1446.

    Article  CAS  PubMed  Google Scholar 

  87. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior Therapy and sibutramine for the treatment of adolescent obesity. JAMA 2003;289:1805–1812.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrine Unit, Second Department of Obstetrics and Gynecology, Aretaieion Hospital, Medical School of Capodistriakon Athens University, Athens, Greece

    Carolina Koliopoulos MD & George Creatsas MD

Authors
  1. Carolina Koliopoulos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Creatsas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Endocrine Section of First Department of Internal Medicine, Athens University School of Medicine, Athens, Greece

    Evanthia Diamanti-Kandarakis MD, PhD

  2. Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA

    John E. Nestler MD

  3. Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece

    Dimitrios Panidis MD, PhD

  4. Endocrinology Unit, Department of Internal Medicine and Gastroenterology and C.R.B.A., S. Orsola-Malpighi Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy

    Renato Pasquali MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc.

About this chapter

Cite this chapter

Koliopoulos, C., Creatsas, G. (2007). Therapeutic Aspects of Polycystic Ovary Syndrome in Adolescence. In: Diamanti-Kandarakis, E., Nestler, J.E., Panidis, D., Pasquali, R. (eds) Insulin Resistance and Polycystic Ovarian Syndrome. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-59745-310-3_27

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-310-3_27

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-763-1

  • Online ISBN: 978-1-59745-310-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation